Den overordnede procentdel af patienter, som oplevede symptomer efter dosering, var henholdsvis 44, 7%, 16, 7% og 10, 2% efter første, anden og tredje infusion.
The overall percentage of patients who experienced post-dose symptoms were 44.7%, 16.7% and 10.2% after the first, second and third infusion, respectively.